

*INVESTOR PRESENTATION*  
*JUNE 2017*

# Disclaimer

*This presentation and the information contained herein are confidential and the property of Scythian Biosciences Inc. This presentation is intended to introduce you to Scythian. The information presented is not, and is not intended to be, an offer to sell or the solicitation of an offer to buy any security of Scythian. It does not constitute an offer, solicitation or sale of any securities of Scythian. It is not a prospectus or an offering memorandum.*

*Statements made are as of the date hereof; delivery of this presentation does not at any time create an implication that the information contained herein is accurate as of any date subsequent to today's date. Scythian has not undertaken any independent verification of industry data, trends, or third party information used herein.*


*This presentation contains forward looking information. These statements relate to future events and future performance. Forward-looking statements are based on the opinions and assumptions of management as of the date made, and are subject to a variety of risks and other factors that could cause actual events/results to differ materially from these forward looking statements. Although management believes that the expectations are reasonable, there can be no assurance that such expectations will prove to be correct; these statements are no guarantee of future performance and involve known and unknown risks, uncertainties and other factors. We cannot guarantee future results, performance, or achievements and no representations are made that actual results achieved will be the same. Nothing herein can be assumed or predicted, and readers are strongly encouraged to learn more and seek independent advice before relying on any information presented.*

# Mission Statement

*Scythian Biosciences Inc. has commenced its long term goal to be the premier pharmaceutical development company that harnesses the development of cannabinoid and non-cannabinoid based pharmaceutical drug therapies.*


# What is Traumatic Brain Injury (TBI)

*Bump, blow or jolt to the head or a penetrating head injury that disrupts the normal function of the brain.*



# Market Size


2013 TBI Injuries




Direct and Indirect  
Medical Cost of TBI  
injuries - \$76.5 billion

Source: Centers for Disease Control and Prevention: Traumatic Brain Injury & Concussion - <https://www.cdc.gov/traumaticbraininjury/severe.html>

% TBI Injuries From all Injuries in 2013



# Our Solution



*Inhibit  
immune  
response*



*Inhibit  
inflammation*

# Industry Comparable

Company	Market Cap	Products	Product Type	Indications(s)	Regulatory Path	Founded
GW Pharmaceuticals (NASDAQ: GWPH)	2.525B	Sativex, Epidiolex (PhIII)	Plant cannabinoid therapeutics	MS/Spasticity, Epilepsy	FDA	1998
Insys Therapeutics (NASDAQ: INSY)	784.05M	Syndros (Oral Dronabinol)	Synthetic and plant cannabinoids	Weight loss, Nausea, Vomiting, Anorexia	FDA	1990
Axim Biotechnologies (NASDAQ: AXIM)	527.8M	MedChew (PhI)	Plant cannabinoid therapeutics	MS/Spasticity, Parkinson's, Crohn's	FDA/EMA (2018)	2014

# Industry Comparable Cont.

Company	Market Cap	Products	Product Type	Indications(s)	Regulatory Path	Founded
Corbus Pharmaceuticals (NASDAQ: CRBP)	298.8M	Resunab (PhII)	Synthetic cannabinoid	Cystic Fibrosis, Sclerosis, Lupus	FDA	2014
Arena Pharmaceuticals (NASDAQ: ARNA)	431.71M	ADP371 (PhII)	Synthetic cannabinoid	Crohn's	FDA	1997
CARA Therapeutics (NASDAQ: CARA)	563.93M	CR701 (Pre)	Synthetic cannabinoid	Neuropathic Pain	FDA (2017)?	2004
Zynerba Pharmaceuticals (NASDAQ: ZYNE)	237.04M	Zyn001, Zyn002 (PhII)	Synthetic cannabinoid	Neuropathic Pain, Epilepsy	FDA	2007

# Project Time Line



*Year 2017*













*Year 2018*



*Year 2019-2021*

# 2017

Timeline	June	July	Aug. - Nov.	December
Pre-clinical	  <ul style="list-style-type: none"> <li>Control studies preparing for compound</li> <li>Equipment calibration</li> <li>Will do 1 model at a time <ul style="list-style-type: none"> <li>Blunt</li> <li>Blast</li> <li>Fluid Percussion</li> </ul> </li> <li>Team in PLACE</li> </ul>   <ul style="list-style-type: none"> <li>FDA Consultant – Call June 9<sup>th</sup></li> <li>Collect data for Pre-IND meeting</li> </ul>	  <ul style="list-style-type: none"> <li>Start with Compound</li> <li>Start with Blunt model</li> <li>Acute and Chronic injured rats</li> <li>Will do CBD and HU211 alone and in combo</li> <li>1 day dosing up to 7 days</li> <li>1, 2, 4 week compound animals</li> <li>Longer term animals start clock</li> <li>Understand compound together and separately</li> </ul> 		  <ul style="list-style-type: none"> <li>Blunt model most promising TBI model, first will be done and will have good data</li> <li>Analyze all domains and continue these domains with other TBI models</li> <li>Cognitive: <ul style="list-style-type: none"> <li>Water Maze</li> <li>Attention</li> <li>Memory</li> </ul> </li> <li>Behavior: <ul style="list-style-type: none"> <li>Pain / Anxiety / etc.</li> </ul> </li> <li>Hearing</li> <li>Balance</li> <li>Nutrition</li> </ul> 

2017

Timeline	June	July	Aug. - Nov.	December
Clinical				
	<ul style="list-style-type: none"> <li>• Adult mTBI clinic up and running</li> <li>• Age 18 +</li> <li>• N = 100</li> <li>• Non-compound controls</li> <li>• Database (RedCAP) set up</li> <li>• Collect demographics</li> <li>• Standard neuro screenings</li> <li>• Decide on first phase outcome measures</li> </ul>	<ul style="list-style-type: none"> <li>• Outcome measures include:                             <ul style="list-style-type: none"> <li>• Cognitive</li> <li>• Behavioral</li> <li>• Vestibular</li> <li>• Vision</li> <li>• Pain</li> <li>• Psychosocial</li> </ul> </li> </ul>		

2018

Timeline	January	February	March	April-Aug+
Pre-clinical				
Budget: \$2M				
	<div> <div></div> <div></div> <div> <ul style="list-style-type: none"> <li>Start Blast Model</li> <li>Examine safety</li> <li>Continue to develop dosing paradigm</li> </ul> </div> <div> <ul style="list-style-type: none"> <li>Fast Track APP and IND ready?</li> </ul> </div> <div> <ul style="list-style-type: none"> <li>Start Fluid Percussion model and Translational work</li> </ul> </div> </div>			

2018				
Timeline	January	February	March	April-Aug+
<b>Clinical</b>  <b>Budget: \$1.7M</b>				
	<ul style="list-style-type: none"> <li>• <i>DEFINE primary and secondary outcome measures for compound patience</i></li> <li>• <i>If OK with FDA, can start safety studies, small groups of patients</i> <ul style="list-style-type: none"> <li>• <i>Test sensitivity of measures</i></li> <li>• <i>Reliability and validity studies</i></li> </ul> </li> </ul>			

2019-2021			
Timeline	2019	2020	2021
<b>Pre-clinical &amp; clinical</b> <i>Phase 3</i>  <b>Budget: ~\$15M</b>			
	<ul style="list-style-type: none"> <li>• <i>FDA approval for larger clinical randomized trial</i></li> </ul>		

# Leadership



Jonathan Gilbert  
CEO Chairman &  
Director

## Accomplishments & Experience

- Two decades of corporate finance and technology start-up development.
- President of New York-based Gilbert Capital Management Corp. for 14 years.
- Business development manager at Decision Nutrition, a multimedia nutrition consultancy company.

## Leadership Strengths

- Corporate Operations
- Corporate Development
- Go-to-Market Strategies
- Contract Negotiations
- Sales Enablement/Marketing
- Talent Management

# Management



DAVID SCHRADER COO

## Professional

- Developer and inventor of the Company's TBI drug therapy
- Moritt Hock & Hamroff LLP– Partner; Attorney
- Prior: Laconia Capital – V.P. and General Counsel
- K-Tex, LLC – General Counsel and V.P. of Strategic Mgmt
- Epic Wound Care, LLC – Executive V.P.

## Education

- M.B.A. and M.Sc. Strategic Mgmt. – Kelley School of Business
- M.G.M. – Thunderbird School of Global Mgmt.
- LL.M in Business Transactions – Univ. of Alabama School of Law
- J.D. - Benjamin N. Cardozo School of Law
- B.A. – Biology (Cell/Molecular Biology and Biochemistry) - Johns Hopkins University



JONATHAN HELD CFO

- Chartered professional accountant with CFO level experience with both private and public companies
- Global startup specialist both domestic and international
- Public market transactions including Initial Public Offerings, Reverse Takeovers and financings
- Bachelor of Mathematics and Masters of Accounting from the University of Waterloo

# The Board



Gary Leong

- Chief Scientific Officer of Aphria Inc.
- President of Neautrical Solutions Inc.



Michael Petter

- CEO of Mikrofax an eProcurement Solutions, an international San Francisco based software development company that specializes in SaaS based supply chain management workflow tools.



Peter Benz

- Serial entrepreneur
- Chairman of Optex Systems holdings Inc.
- Director and audit committee member of Cogint Inc., Lilis Energy Inc. and uSell.com Inc.
- Chairman Viking Asset Management LLC.



Roger Rai

- Managing Director of E. S. Rogers Enterprises and President of R3 Concepts Inc.
- Director of the ONEXONE foundation

# The University of Miami Miller School of Medicine Lead Research Team



*Gillian A. Hotz, PhD*

*Director of the University of Miami  
UConcussion Program*

*Director of KIDZ Neuroscience Center,  
at The Miami Project to Cure Paralysis  
Nationally recognized as a behavioral  
neuroscientist*

*Expert in pediatric, adult neurotrauma  
and concussion prevention and  
management*



*Dalton Dietrich, PhD*

*Scientific Director, The Miami  
Project to Cure Paralysis, Senior  
Associate Dean for Discovery  
Science, Professor of  
Neurological Surgery, Neurology,  
Biomedical Engineering and Cell  
Biology*



*Bonnie Levin, PhD*

*Professor of Neurology and  
Director of the Division of  
Neuropsychology, Department of  
Neurology*



*Michael Hoffer, MD*

*Professor Otolaryngology  
and Neurotology*

# The Advisory Board



MAGHSOUD DARIANI

- VP of Celgene Corporation
- CEO of Semorex Cancer Therapy
- President of Focus Pharmaceuticals
- Board of Directors, numerous public companies



BART OATES

- President, NFL Alumni Association
- Magna Cum Laude, Juris Doctorate, Seton Hall Law School
- 5-time NFL Pro Bowl player; 3-time Super Bowl Champion



PETER LEVY

- COO and President of two publicly traded companies
- Integrity Monitor, Securities and Exchange Commission
- Expert in Internal Controls and Corporate Governance
- Attorney with over 25 years' experience



SCOTT DAVID  
BORUCHOV

- Radiology, Edison Radiology Group
- Facility Director Advanced Medical Imaging
- Tremendous Access to Head Trauma Patients

# General Cap Structure

Common Shares – 5,257,960

Stock Options – 167,550

Warrants – 719,394

DSU's – 143,750

**Fully Diluted – 6,288,654**

Escrowed Securities:

Common Shares – 1,947,001

DSU's – 105,688

Stock Options – 59,375



# Partnerships



UNIVERSITY OF MIAMI  
MILLER SCHOOL  
of MEDICINE

---



# Go Green

## – Canadian Medical Marijuana Licensing Pending

Source: DELOITTE: Legal weed could be a \$22.6 billion industry in Canada :<http://www.businessinsider.com/deloitte-weed-could-be-226-billion-canada-2016-10>



# *Investor Presentation*

*Thank You*

Jonathan R. Gilbert CEO,  
Scythian Biosciences Inc.  
212-729-9208 | 917-693 0215  
[jgilbert@scythianbio.com](mailto:jgilbert@scythianbio.com) | [www.scythianbio.com](http://www.scythianbio.com)